These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 1836425)
1. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol. Lemay A; Brideau NA; Forest JC; Dodin S; Maheux R Clin Endocrinol (Oxf); 1991 Oct; 35(4):305-10. PubMed ID: 1836425 [TBL] [Abstract][Full Text] [Related]
2. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis. Maouris P; Dowsett M; Rose G; Edmonds DK; Rothwell C; Robertson WR Clin Endocrinol (Oxf); 1990 Oct; 33(4):539-46. PubMed ID: 2146047 [TBL] [Abstract][Full Text] [Related]
3. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Dodin S; Lemay A; Maheux R; Dumont M; Turcot-Lemay L Obstet Gynecol; 1991 Mar; 77(3):410-5. PubMed ID: 1825135 [TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Dlugi AM; Rufo S; D'Amico JF; Seibel MM Fertil Steril; 1988 May; 49(5):913-6. PubMed ID: 3129319 [TBL] [Abstract][Full Text] [Related]
5. Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis. Golland IM; Vaughan-Williams CA; Shalet SM; Laing I; Elstein M Acta Endocrinol (Copenh); 1990 Oct; 123(4):405-10. PubMed ID: 2146853 [TBL] [Abstract][Full Text] [Related]
6. Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors. Crook D; Gardner R; Worthington M; Nolan J; Stevenson JC; Shaw RW Horm Res; 1989; 32 Suppl 1():157-60. PubMed ID: 2533147 [TBL] [Abstract][Full Text] [Related]
7. Circulating lipid and lipoprotein concentrations during danazol and high-dose medroxyprogesterone acetate therapy of endometriosis. Telimaa S; Penttilä I; Puolakka J; Rönnberg L; Kauppila A Fertil Steril; 1989 Jul; 52(1):31-5. PubMed ID: 2526031 [TBL] [Abstract][Full Text] [Related]
8. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. Välimäki M; Nilsson CG; Roine R; Ylikorkala O J Clin Endocrinol Metab; 1989 Dec; 69(6):1097-103. PubMed ID: 2531153 [TBL] [Abstract][Full Text] [Related]
9. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team. Shaw RW Fertil Steril; 1992 Aug; 58(2):265-72. PubMed ID: 1386029 [TBL] [Abstract][Full Text] [Related]
10. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results. Venturini PL; Fasce V; Costantini S; Anserini P; Cucuccio S; de Cecco L Fertil Steril; 1990 Dec; 54(6):1021-7. PubMed ID: 2147154 [TBL] [Abstract][Full Text] [Related]
11. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis. Stevenson JC; Lees B; Gardner R; Shaw RW Horm Res; 1989; 32 Suppl 1():161-3; discussion 164. PubMed ID: 2533148 [TBL] [Abstract][Full Text] [Related]
12. Goserelin versus danazol in the treatment of endometriosis. Giorgino FL; Cetera C; de Laurentiis G Clin Exp Obstet Gynecol; 1991; 18(2):127-31. PubMed ID: 1833094 [TBL] [Abstract][Full Text] [Related]
13. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study. Dmowski WP; Radwanska E; Binor Z; Tummon I; Pepping P Fertil Steril; 1989 Mar; 51(3):395-400. PubMed ID: 2493400 [TBL] [Abstract][Full Text] [Related]
14. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group. Rock JA; Truglia JA; Caplan RJ Obstet Gynecol; 1993 Aug; 82(2):198-205. PubMed ID: 8336864 [TBL] [Abstract][Full Text] [Related]
15. Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol. Burry KA; Patton PE; Illingworth DR Am J Obstet Gynecol; 1989 Jun; 160(6):1454-9; discussion 1459-61. PubMed ID: 2525337 [TBL] [Abstract][Full Text] [Related]
16. On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Franssen AM; van der Heijden PF; Thomas CM; Doesburg WH; Willemsen WN; Rolland R Fertil Steril; 1992 May; 57(5):974-9. PubMed ID: 1533376 [TBL] [Abstract][Full Text] [Related]
17. Changes of plasma lipids and lipoprotein levels during danazol treatment for endometriosis. Schweppe KW; Assmann G Horm Metab Res; 1984 Nov; 16(11):593-7. PubMed ID: 6510890 [TBL] [Abstract][Full Text] [Related]
19. Rationale in use of LHRH analogues in endometriosis. Shaw RW Horm Res; 1989; 32 Suppl 1():110-4. PubMed ID: 2533143 [TBL] [Abstract][Full Text] [Related]
20. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. Cheng MH; Yu BK; Chang SP; Wang PH J Chin Med Assoc; 2005 Jul; 68(7):307-14. PubMed ID: 16038370 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]